Author

Marc Ferrante 1

1 University Hospitals Leuven

New treatment modalities: Stem cells and other

Marc Ferrante

Novel developments: Jak-inhibitors in medical treatment

Marc Ferrante

OPEN LABEL OBSERVATIONAL STUDY EVALUATING THE EFFECT OF INDUCTION THERAPY WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE INFLAMMATORY BOWEL DISEASE INTOLERANT/RESISTANT TO AT LEAST TWO BIOLOGICALS

Martine De Vos, Barbara Dhooghe, Severine Vermeire, Edouard Louis, Mana Fazia, An Elewaut, Peter Bossuyt, Filip Baert, Catherine Reenaers, Marc Van Gossum, Elisabeth Macken, Marc Ferrante, Pieter Hindryckx, Sophie De Wit, Tom Holvoet, Denis Franchimont

Optimising surgical outcome: Peri-operative treatment, timing and techniques

Marc Ferrante

Optimising surgical outcome: Peri-operative treatment, timing and techniques

André D'Hoore, Marc Ferrante

PATIENT REPORTED OUTCOME SEVERITY DOES NOT IMPACT ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF SONIC

Neeraj Narula, Emily C.L. Wong, Achuthan Aruljothy, Parambir Dulai, Jean-Frederic Colombel, John K. Marshall, Marc Ferrante, Walter Reinisch

PIT PATTERN ANALYSIS WITH HIGH DEFINITION CHROMO-ENDOSCOPY AND NBI IN ULCERATIVE COLITIS: CAN WE RULE OUT DYSPLASIA ?

Raf Bisschops, Talat Bessissow, Pradeep Bhandari, Evelien Dekker, James Edward East, Ana Ignjatovic, Adolfo Para Blanco, Krish Ragunath, Edmund Derbyshire, Erik Jan Schoon, Paul Rutgeerts, Marc Ferrante, Matt Rutter

PREDICTING TOFACITINIB INDUCED ENDOSCOPIC RESPONSE IN ULCERATIVE COLITIS THROUGH A MUCOSAL BIOMARKER

Bram Verstockt, Sare Verstockt, Dahham Alsoud, João Sabino, Marc Ferrante, Severine Vermeire

PRIMARY STUDY RESULTS FROM GO OBSERVE: A REAL-WORLD EUROPEAN PROSPECTIVE SINGLE-ARM OBSERVATIONAL COHORT STUDY OF PATIENT-REPORTED CONTINUOUS CLINICAL RESPONSE TO GOLIMUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Marc Ferrante, Anja Schirbel, Marieke J. Pierik, Thomas Haas, Mathurin Flamant, Tony Terzis, Ahmed Khalifa, George Philip, Freddy Cornillie, Alan Meehan, Marinella Govoni

PROGNOSTIC FACTORS FOR LONG-TERM INFLIXIMAB TREATMENT IN CROHN?S DISEASE PATIENTS: A 20-YEAR SINGLE CENTER EXPERIENCE

Thomas Billiet, Isabelle Cleynen, Vera Ballet, Marc Ferrante, Gert Van Assche, Ann Gils, Severine Vermeire

Item 51 - 60 / 93
1
...
3 4 5
6
7 8 9
...
10